• Benzyl Quinolone Carboxylic Acid: Advanced M1 Modulation Wor

  2026-05-19

  Benzyl Quinolone Carboxylic Acid (BQCA) is redefining experimental rigor in cognitive and Alzheimer's disease research by enabling precise, selective potentiation of M1 muscarinic acetylcholine receptor signaling. This article delivers actionable protocol enhancements, troubleshooting strategies, and critical insights from the latest GRK bias studies to maximize BQCA’s translational impact.

• Epigenetic Inhibitor Signatures in Melanoma Immunotherapy Re

  2026-05-18

  Anichini et al. systematically profiled immune-related gene expression changes induced by distinct epigenetic inhibitors in melanoma, highlighting guadecitabine as the most robust inducer of immunomodulatory signatures. These findings provide a molecular rationale for integrating DNA methyltransferase inhibitors with immune checkpoint blockade to overcome resistance and improve therapeutic outcomes.

• Dynasore (A1605): Practical Guidance for Dynamin GTPase Inhi

  2026-05-18

  Dynasore is a cell-permeable, reversible inhibitor of dynamin family GTPases, widely applied to block dynamin-mediated endocytosis in cell-based research. Researchers use Dynasore to dissect membrane trafficking, synaptic vesicle endocytosis, and signal transduction pathways. It is not suitable for applications requiring permanent inhibition or water-based solubility.

• Triacetin Drives Toxic Aldehyde Formation in E-Cigarette Aer

  2026-05-17

  This study demonstrates that triacetin, a common e-cigarette flavor additive, significantly increases the formation of harmful aldehydes in aerosol emissions. By using isotope labeling and NMR, the authors reveal a catalytic mechanism involving ester hydrolysis, offering new evidence on inhalation risks associated with glyceryl triacetate-containing e-liquids.

• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-05-16

  Wang et al. (2024) identify a METTL16-SENP3-LTF signaling axis that confers resistance to ferroptosis and promotes tumorigenesis in hepatocellular carcinoma (HCC). Their mechanistic work reveals how m6A RNA modification modulates iron metabolism, offering new targets for overcoming ferroptosis resistance and advancing iron chelation-based strategies in cancer research.

• Fusobacterium nucleatum EVs Promote CRC Colonization via Mem

  2026-05-15

  This study uncovers how extracellular vesicles (EVs) from Fusobacterium nucleatum accumulate in colorectal cancer (CRC) tissues and facilitate bacterial colonization through membrane fusion and surface transfer of the adhesin FomA. These findings clarify a key mechanism in microbial niche preparation within tumors and offer new directions for endocytosis-focused cancer research.

• Panobinostat Targets Epigenetic Vulnerabilities in MLL-ALL

  2026-05-15

  This study demonstrates that the HDAC inhibitor panobinostat exerts potent anti-leukemic effects in MLL-rearranged acute lymphoblastic leukemia by disrupting H2B ubiquitination via the RNF20/RNF40/WAC axis. The findings highlight a convergence of epigenetic vulnerabilities in aggressive infant ALL and offer insights for developing targeted therapeutic strategies.

• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-05-14

  Wang et al. delineate a novel METTL16-SENP3-LTF signaling cascade that promotes ferroptosis resistance and tumor growth in hepatocellular carcinoma (HCC) by controlling iron metabolism at the post-transcriptional level. Their findings spotlight a targetable molecular pathway for sensitizing HCC to ferroptosis, with implications for future therapeutic strategies.

• Nicotine Signaling Accelerates CKD Progression: Mechanistic

  2026-05-14

  Jain and Jaimes (2013) provide a comprehensive mechanistic review revealing how nicotine signaling, through non-neuronal nicotinic acetylcholine receptors in the kidney, accelerates chronic kidney disease (CKD) progression among smokers. Their synthesis of clinical and experimental data highlights oxidative stress and pro-fibrotic pathways as central mediators, suggesting new molecular intervention points for CKD research.

• α-Amanitin in Functional Transcriptomics: Precision and Pitf

  2026-05-13

  Explore the nuanced application of α-Amanitin as a benchmark RNA polymerase II inhibitor for cutting-edge transcriptional regulation research. This article delivers advanced assay guidance, highlights protocol caveats, and uniquely integrates insights from post-transcriptional epigenetics.

• CUDC-907: Technical Protocols for Dual PI3K and HDAC Inhibit

  2026-05-13

  CUDC-907 offers researchers a practical approach to simultaneous inhibition of class I PI3K isoforms and select HDACs in established cancer cell models. It is strictly intended for controlled laboratory workflows and not for diagnostic, therapeutic, or clinical use.

• EZ Cap™ Firefly Luciferase mRNA: Optimizing Reporter Assays

  2026-05-12

  EZ Cap™ Firefly Luciferase mRNA with Cap 1 structure unlocks next-level sensitivity and stability for bioluminescent reporter assays in both in vitro and in vivo contexts. This article delivers actionable workflow enhancements and troubleshooting strategies, grounded in recent advances in lipid nanoparticle delivery and mRNA engineering.

• P2Y11 Antagonist NF 340: Applied Workflows in Cancer & Immun

  2026-05-12

  NF 340, a selective P2Y11 antagonist from APExBIO, empowers researchers to precisely dissect GPCR signaling and inflammation pathways in advanced oncology and immunology models. This article delivers real-world protocols, troubleshooting insights, and evidence-driven rationale for integrating NF 340 into translational research workflows.

• Auranofin as a Thioredoxin Reductase Inhibitor in Cancer Wor

  2026-05-11

  Auranofin's nanomolar potency as a thioredoxin reductase inhibitor enables precise modulation of redox balance, apoptosis, and radiosensitivity in tumor models. This guide delivers protocol-ready parameters, troubleshooting advice, and experimental insights for researchers seeking reproducible outcomes in cancer and mechanotransduction studies.

• Protease Inhibitor Cocktail EDTA-Free: Ensuring Protein Inte

  2026-05-11

  Discover how the Protease Inhibitor Cocktail EDTA-Free (100X in DMSO) empowers advanced protein extraction and signaling studies. This article uniquely explores its decisive role in preserving protein integrity during challenging workflows, including cutting-edge mitochondrial research.

16363 records 1/1091 page Next 12345 下5页 Last page